The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC. Key Messages Venous thromboembolism (VTE) is common in COVID-19 patients, especially those in the intensive care unit. Prophylactic anticoagulation is recommended in all patients with COVID-19 unless contraindicated.

Figure legendFigure 1 A, B, Computed tomography of chest showing groundglass densities present bilaterally, extending from the hilum, more prominent toward the periphery in the left upper lobe and middle lobe.

No abstract

It can be concluded from the present study that an enhanced oxidative stress coupled with endothelial dysfunction as indicated by reduced activity of NO pathway and enhanced expression of sVCAM-1 play an important intermediary role in the pathogenesis of macrovascular complications in type 2 DM.

No abstract